tiprankstipranks
Trending News
More News >
Sensorion SAS (FR:ALSEN)
:ALSEN
Advertisement

Sensorion SAS (ALSEN) AI Stock Analysis

Compare
10 Followers

Top Page

FR:ALSEN

Sensorion SAS

(Frankfurt:ALSEN)

Rating:51Neutral
Price Target:
€0.50
▲(38.89%Upside)
Sensorion SAS's overall stock score reflects its financial challenges and valuation concerns, despite some positive technical indicators. The company's revenue growth and strong equity position are overshadowed by significant net losses and negative cash flows. Improvement in operational efficiency and profitability is crucial for future success.
Positive Factors
Clinical Trial Progress
Sensorion has completed enrollment for its Phase 2a study of SENS-401, indicating progress in their clinical trial efforts.
Drug Development
SENS-501 was safe and well-tolerated in all three children receiving the surgery and therapy.
Financial Stability
Sensorion ended the year with EUR77m in cash after two successful funding rounds, ensuring financial stability.
Negative Factors
Competitive Pressure
Competitor's encouraging updates and fast enrollment in trials raise the stakes for ALSEN's upcoming readout.
Drug Effectiveness Doubts
There are lingering uncertainties around SENS-401, with mean hearing loss similar between treated and control groups, creating doubts about its effectiveness.
Regulatory Delays
The expected IND submission for the GJB2-mediated hearing loss program has been delayed.

Sensorion SAS (ALSEN) vs. iShares MSCI France ETF (EWQ)

Sensorion SAS Business Overview & Revenue Model

Company DescriptionSensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
How the Company Makes MoneySensorion SAS generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's main revenue streams include licensing agreements, collaborations with other pharmaceutical companies, and potentially, sales of approved therapies. Significant factors contributing to its earnings include successful clinical trials, regulatory approvals, and strategic partnerships that facilitate research and development or enhance market access. Sensorion may also benefit from grants and funding opportunities specific to innovation in biotechnology.

Sensorion SAS Financial Statement Overview

Summary
Sensorion SAS shows potential with revenue growth and a solid equity base. However, substantial net losses and negative cash flows present significant challenges. The company needs to focus on cost control and operational efficiency to improve profitability and cash flow stability.
Income Statement
45
Neutral
Sensorion SAS has experienced revenue growth, but profitability remains a concern. While total revenue increased from the previous year, the company continues to operate at a significant net loss. The gross profit margin is positive, indicating effective revenue management, but negative EBIT and EBITDA margins reflect high operational costs. The consistent net loss indicates a need for improved cost management and revenue enhancement strategies.
Balance Sheet
60
Neutral
The company maintains a strong equity position with a low debt-to-equity ratio, suggesting financial stability. Stockholders' equity has improved significantly, indicating investor confidence and capital raising success. However, the persistent net losses continue to erode equity value. The equity ratio is healthy, reflecting a strong capital structure, but ongoing losses could pose risks if not addressed.
Cash Flow
50
Neutral
Sensorion SAS exhibits a challenging cash flow position with negative operating and free cash flows. Despite generating significant financing cash flow, largely from equity raises, the company has been unable to generate positive free cash flow. The free cash flow to net income ratio remains negative, reflecting ongoing operational challenges. A focus on improving operating cash flow is essential for long-term financial health.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.65M5.70M4.93M4.26M2.35M
Gross Profit6.65M3.79M4.16M3.75M1.94M
EBITDA-27.58M-21.33M-22.44M-14.61M-8.85M
Net Income-25.97M-22.06M-23.21M-15.14M-8.98M
Balance Sheet
Total Assets89.28M46.50M38.93M59.02M67.87M
Cash, Cash Equivalents and Short-Term Investments76.98M36.97M26.20M50.00M62.17M
Total Debt2.20M2.87M3.76M3.99M3.88M
Total Liabilities17.14M13.23M17.06M15.03M9.52M
Stockholders Equity72.14M33.27M21.87M43.98M58.35M
Cash Flow
Free Cash Flow-22.45M-21.94M-22.92M-11.81M-5.48M
Operating Cash Flow-21.33M-21.07M-21.41M-10.77M-5.31M
Investing Cash Flow-11.13M-381.06K-1.54M-1.07M-164.93K
Financing Cash Flow62.26M32.20M-820.68K-326.07K37.23M

Sensorion SAS Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.36
Price Trends
50DMA
0.35
Positive
100DMA
0.38
Negative
200DMA
0.52
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
56.61
Neutral
STOCH
68.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.35, and below the 200-day MA of 0.52, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.61 is Neutral, neither overbought nor oversold. The STOCH value of 68.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALSEN.

Sensorion SAS Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.59B0.18-63.05%2.16%16.16%0.65%
51
Neutral
€109.42M-49.28%55.02%
$203.81M-160.99%
€268.10M
€112.54M-220.48%
€144.59M3.6586.78%
39
Underperform
€72.17M
44.34%-27.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ALSEN
Sensorion SAS
0.36
-0.27
-42.86%
IPHYF
Innate Pharma SA
1.31
-0.97
-42.54%
GB:0QAV
Nanobiotix
5.70
0.85
17.53%
GB:0OCQ
Transgene
0.90
-0.21
-18.92%
DE:6OP
OSE Immunotherapeutics SA
6.30
-1.25
-16.56%
FR:MAAT
MaaT Pharma
4.68
-2.88
-38.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025